Today's Date: October 2, 2023
Veteran Tech Exec Sissie Hsiao joins Bumble Inc. Board of Directors   •   Simon® Earns GRESB Green Star   •   EPA Names Clorox as 2023 Safer Choice Partner of the Year for Advancing Ingredient and Product Safety   •   Essential Utilities Completes Sale of West Virginia Gas Utility Assets   •   Honouliuli National Historic Site Commemorated with Blessing Event and Plaque Dedication Ceremony   •   Feinstein Institutes’ Ross Prize awardees win 2023 Nobel Prize in Physiology or Medicine   •   How to Make a Difference This Halloween   •   J&J Patent Move Must be First of Many, says AHF   •   Remedios Varo Exhibition at Art Institute of Chicago Celebrates Hispanic Heritage Through Art   •   BWX Technologies to Announce Third Quarter 2023 Results on Wednesday, November 1   •   iQor Celebrates Customer Service Week 2023   •   Carmen M. Hernández Joins HITN’s Board of Directors   •   Empire State Realty Trust Announces Acquisition of Prime Retail Asset in Williamsburg, Brooklyn, as Part of Capital Recycling Pr   •   Most Women Skipping Annual Mammograms, According to New MedStar Health Survey   •   Global Gaming Women Announces Event Line-up at Global Gaming Expo 2023 including the 13th Annual Kick Up Your Heels Fundraiser   •   U.S. Postal Service Commemorates Legacy of Ruth Bader Ginsburg   •   Andreozzi + Foote File Lawsuits as the New Maryland Child Victims Law Takes Effect   •   Link Logistics Publishes Third Annual ESG Report   •   Afya Limited to Report Third Quarter and Nine Months 2023 Financial Results on November 13th   •   ComplyCube Unveils No-ID Age Estimation to Address Growing Global Age-Restriction Regulations
Bookmark and Share

EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer

SHANGHAI, China , June 08 /Businesswire/ - EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, today announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer (CMO). As CMO, Dr. Zhu will be responsible for overseeing all clinical development activities for the company’s clinical stage assets. This strategic addition to the executive team further strengthens the company's commitment to innovation and mission of advancing cutting-edge bispecific therapies. Dr. Zhu replaces EpimAb’s previous CMO, Dr. Bin Peng, who recently retired from EpimAb after five years of service at the company.

With around two decades of experience in the biotech industry, Dr. Zhu brings an outstanding track record and expertise that spans across early to late-stage development in oncology and immunology to EpimAb. Before joining EpimAb, Dr. Zhu was the CMO at MaxiNovel Pharmaceuticals, and prior to this, he held leadership positions in Clinical Development and Translational Medicine at Roche, Takeda and Henlius, where he made significant contributions to developing and executing overall clinical strategies, and evaluating and driving strategic collaborations. Dr. Zhu obtained his Bachelor’s and Medical Degrees (combined 7 year program) at Nanjing University Medical School, and completed his Ph.D. training in Microbiology & Immunology (Major in Virology) at the University of Rochester School of Medicine & Dentistry.

"We are excited to welcome Dr. Zhu as our new Chief Medical Officer," said Dr. Chengbin Wu, Founder and CEO of EpimAb. "His extensive knowledge in the oncology and immunology fields, plus a wealth of experience designing and leading early and late-stage clinical programs align perfectly with our vision. We are confident that Dr. Zhu's leadership skills and expertise will accelerate our mission of developing breakthrough therapies for diseases with significant unmet need."

Dr. Zhu commented, "I am honored to join and collaborate with the dedicated team at EpimAb. With its multiple proprietary and unique platform technologies and an exceptional R&D team, EpimAb has generated several differentiated clinical programs with tremendous potential. I look forward to further advancing these programs and contributing to the future success of the company.”

About EpimAb Biotherapeutics

EpimAb Biotherapeutics is a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies. Utilizing our broad range of in-house research and technology capabilities, including the proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) and MAT-Fab (Monovalent Asymmetric Tandem Fab) bispecific platforms, EpimAb is generating and globally advancing a unique pipeline of transformative preclinical and clinical assets that aim to benefit cancer patients. For further information, please visit:

STORY TAGS: Personnel, Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, China, Asia Pacific,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News